Indoco Remedies Secures EU GMP Certification for Goa Manufacturing Plant
New Delhi: Indoco Remedies Limited has announced that its Goa Unit-I manufacturing facility for solid oral dosage forms (Plant I) has received European Union Good Manufacturing Practice (EU GMP) certification from the Malta Medicines Authority, following a successful regulatory inspection conducted at the facility.
The company disclosed the development informing that the Malta Medicines Authority inspected the manufacturing facility located in Goa from November 19 to November 24, 2025.
According to the company, the inspection concluded successfully, and the Malta Medicines Authority has issued EU GMP certification, confirming that the Goa Plant-I facility complies with the Good Manufacturing Practice requirements as referred to in the European Commission (EC) Directive.
Commenting on the development, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "Compliance is a core value that drives our quality systems. This approval reinforces our commitment to delivering highest quality healthcare to our customers worldwide."
The company stated that the certification further strengthens its commitment to maintaining internationally accepted quality standards across its manufacturing operations while supporting its presence in regulated global markets. According to the Indoco Remedies press release, the company is a fully integrated, research-oriented pharmaceutical company with a strong global presence. It reported a turnover of US$175 million and employs more than 6,000 people, including over 300 skilled scientists and field staff.
Indoco currently operates 10 manufacturing facilities, comprising six finished dosage formulation (FDF) plants and four active pharmaceutical ingredient (API) facilities, supported by a state-of-the-art research and development centre and a Contract Research Organisation (CRO) facility. The manufacturing sites have been approved by several international regulatory authorities, including the US Food and Drug Administration (USFDA) and the UK Medicines and Healthcare products Regulatory Agency (UK-MHRA).
The company develops and manufactures a broad range of pharmaceutical products for both the Indian and international markets. It generates more than 109 million prescriptions annually from over 2,50,000 doctors across multiple specialties. Indoco has 10 domestic marketing divisions with a strong portfolio spanning gastro-intestinal disorders, respiratory diseases, anti-infectives, stomatologicals, ophthalmics, nutritionals, cardiovascular diseases, anti-diabetics, pain management and gynaecology.
The company's leading brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Otorex, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa and MCBM 69. Indoco also maintains partnerships with several large generic pharmaceutical companies across global markets.
The company stated that the successful inspection and certification underscore its continued focus on quality compliance and regulatory excellence in pharmaceutical manufacturing.
